Forschung

Forschung im NIK

Autoren Titel Publikation

Gardill K, Schüpbach M

Ausgeprägte proximal betonte Veränderungen in Hochvoltstimulation und Nervensonographie bei langjähriger therapienaiver CIDP-Variante

 Nervenarzt 2021;92(2):161-165

Halbherr S, Lerch S, Bellwald S, Polakova P, Bannert B, Roumet M, Charles RP, Walter MA, Bernasconi C, Halbherr VL, Peitsch C, Baumgartner PC, Kaufmann C, Aires V, Mattle HP, Kaelin-Lang A, Hartmann A, Schuepbach M

Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial)

 PLoS Med. 2025 May 13;22(5):e1004472

Phase 2 study, in preparation

Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

 NCT06431971

Publikationen mit NIK-Affiliation

  • Benninger D, Schüpbach M. Tiefe Hirnstimulation [Deep brain stimulation]. Ther Umsch. 2018;75(7):425-431. German. doi: 10.1024/0040-5930/a001019. PMID: 30935352.
  • Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology. 2019 Mar 5;92(10):e1109-e1120. doi: 10.1212/WNL.0000000000007037. Epub 2019 Feb 8. Erratum in: Neurology. 2019 Jun 11;92(24):1166. doi: 10.1212/WNL.0000000000007420. PMID: 30737338; PMCID: PMC6442017.
  • Knudsen K, Krack P, Tonder L, Houeto JL, Rau J, Schade-Brittinger C, Hartmann A, Hälbig TD, Paschen S, Barbe MT, Kühn A, Fraix V, Brefel-Courbon C, Vesper J, Maltête D, Sixel-Döring F, Weiss D, Witjas T, Thobois S, Agid Y, Schnitzler A, Schuepbach WMM, Timmermann L, Damier P, Vidailhet M, Deuschl G; EARLYSTIM study group. Programming parameters of subthalamic deep brain stimulators in Parkinson’s disease from a controlled trial. Parkinsonism Relat Disord. 2019 Aug;65:217-223. doi: 10.1016/j.parkreldis.2019.05.023. Epub 2019 Jun 18. PMID: 31257096.
  • Barbe MT, Tonder L, Krack P, Debû B, Schüpbach M, Paschen S, Dembek TA, Kühn AA, Fraix V, Brefel-Courbon C, Wojtecki L, Maltête D, Damier P, Sixel-Döring F, Weiss D, Pinsker M, Witjas T, Thobois S, Schade-Brittinger C, Rau J, Houeto JL, Hartmann A, Timmermann L, Schnitzler A, Stoker V, Vidailhet M, Deuschl G; EARLYSTIM study group. Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease With Early Motor Complications. Mov Disord. 2020 Jan;35(1):82-90. doi: 10.1002/mds.27892. Epub 2019 Nov 22. PMID: 31755599.
  • Kaelin-Lang A, You H, Burgunder JM, Lönnfors-Weitze T, Loher TJ, Taub E, Isaias IU, Krauss JK, Michael Schüpbach WM. Bilateral pallidal stimulation improves cervical dystonia for more than a decade. Parkinsonism Relat Disord. 2020 Dec;81:78-81. doi: 10.1016/j.parkreldis.2020.10.028. Epub 2020 Oct 15. PMID: 33075700.
  • Gardill K, Schüpbach M. Ausgeprägte proximal betonte Veränderungen in Hochvoltstimulation und Nervensonographie bei langjähriger therapienaiver CIDP-Variante [Pronounced proximally accentuated changes in high-voltage stimulation and nerve ultrasound in long-standing therapy-naive CIDP variants]. Nervenarzt. 2021 Feb;92(2):161-165. German. doi: 10.1007/s00115-020-01020-w. Epub 2020 Oct 28. PMID: 33112965.
  • Tödt I, Al-Fatly B, Granert O, Kühn AA, Krack P, Rau J, Timmermann L, Schnitzler A, Paschen S, Helmers AK, Hartmann A, Bardinet E, Schuepbach M, Barbe MT, Dembek TA, Fraix V, Kübler D, Brefel-Courbon C, Gharabaghi A, Wojtecki L, Pinsker MO, Thobois S, Damier P, Witjas T, Houeto JL, Schade-Brittinger C, Vidailhet M, Horn A, Deuschl G. The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life. Mov Disord. 2022 Feb;37(2):291-301. doi: 10.1002/mds.28952. Epub 2022 Feb 3. PMID: 35112384.
  • Weiss D, Landoulsi Z, May P, Sharma M, Schüpbach M, You H, Corvol JC, Paschen S, Helmers AK, Barbe M, Fink G, Kühn AA, Courbon CB, Wojtecki L, Damier P, Fraix V, Houeto JL, Regis J, Sixel-Döring F, Pinsker MO, Thobois S, Gharabaghi A, Stoker V, Timmermann L, Schnitzler A, Krack P, Vidailhet M, Deuschl G, Krüger R. Genetic stratification of motor and QoL outcomes in Parkinson’s disease in the EARLYSTIM study. Parkinsonism Relat Disord. 2022 Oct;103:169-174. doi: 10.1016/j.parkreldis.2022.08.025. Epub 2022 Sep 8. PMID: 36117018.
  • Sartori AM, Kiss B, Mordasini L, Pollo C, Schüpbach M, Burkhard FC, Schwab ME, Kaelin-Lang A, Kessler TM. Effects of Deep Brain Stimulation on Lower Urinary Tract Function in Neurological Patients. Eur Urol Focus. 2022 Nov;8(6):1775-1782. doi: 10.1016/j.euf.2022.05.004. Epub 2022 May 31. PMID: 35662503.
  • Averna A, Debove I, Nowacki A, Peterman K, Duchet B, Sousa M, Bernasconi E, Alva L, Lachenmayer ML, Schuepbach M, Pollo C, Krack P, Nguyen TK, Tinkhauser G. Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation. Mov Disord. 2023 May;38(5):818-830. doi: 10.1002/mds.29381. Epub 2023 Mar 28. PMID: 36987385; PMCID: PMC7615852.
  • Bohlhalter S, Benninger D, Brogle D, Hatz F, Kaelin-Lang A, Möller JC, Kägi G, Schuepbach M. Commentary to the controversy: Should asleep deep brain stimulation in Parkinson’s disease be preferred over the awake approach? Swiss Med Wkly. 2024 Aug 9;154:3856. doi: 10.57187/s.3856. PMID: 39137440.
  • Murcia Carretero S, Petermann K, Debove I, Amstutz D, Sousa M, Waskönig J, Diamantaras AA, Tinkhauser G, Nowacki A, Pollo C, Schuepbach M, Krack P, Lachenmayer ML. Quality of Life after Deep Brain Stimulation in Parkinson’s Disease: Does the Target Matter? Mov Disord Clin Pract. 2024 Nov;11(11):1379-1387. doi: 10.1002/mdc3.14199. Epub 2024 Sep 3. PMID: 39225548; PMCID: PMC11542293.
  • Bernasconi E, Amstutz D, Averna A, Fischer P, Sousa M, Debove I, Petermann K, Alva L, Magalhães AD, Lachenmayer ML, Nguyen TK, Schuepbach M, Nowacki A, Pollo C, Krack P, Tinkhauser G. Neurophysiological gradient in the Parkinsonian subthalamic nucleus as a marker for motor symptoms and apathy. NPJ Parkinsons Dis. 2025 Jan 3;11(1):4. doi: 10.1038/s41531-024-00848-2. PMID: 39753562; PMCID: PMC11698975.
  • Colombo A, Bernasconi E, Alva L, Sousa M, Debove I, Nowacki A, Serquet C, Petermann K, Nguyen TAK, Magalhães AD, Lachenmayer L, Waskönig J, Nef T, Schuepbach M, Pollo C, Krack P, Averna A, Tinkhauser G. Finely Tuned γ Tracks Medication Cycles in Parkinson’s Disease: An Ambulatory Brain-Sense Study. Mov Disord. 2025 May;40(5):881-895. doi: 10.1002/mds.30160. Epub 2025 Mar 13. PMID: 40079832; PMCID: PMC12089918.
  • Halbherr S, Lerch S, Bellwald S, Polakova P, Bannert B, Roumet M, Charles RP, Walter MA, Bernasconi C, Halbherr VL, Peitsch C, Baumgartner PC, Kaufmann C, Aires V, Mattle HP, Kaelin-Lang A, Hartmann A, Schuepbach M. Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial). PLoS Med. 2025 May 13;22(5):e1004472. doi: 10.1371/journal.pmed.1004472. PMID: 40359409; PMCID: PMC12101738.